AU2001280093A1 - Method for the prevention and treatment of retinopathy - Google Patents

Method for the prevention and treatment of retinopathy

Info

Publication number
AU2001280093A1
AU2001280093A1 AU2001280093A AU8009301A AU2001280093A1 AU 2001280093 A1 AU2001280093 A1 AU 2001280093A1 AU 2001280093 A AU2001280093 A AU 2001280093A AU 8009301 A AU8009301 A AU 8009301A AU 2001280093 A1 AU2001280093 A1 AU 2001280093A1
Authority
AU
Australia
Prior art keywords
prevention
treatment
retinopathy
retinopathies
various
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280093A
Other languages
English (en)
Inventor
Einar Stefansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001280093A1 publication Critical patent/AU2001280093A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AU2001280093A 2000-08-11 2001-08-10 Method for the prevention and treatment of retinopathy Abandoned AU2001280093A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22435800P 2000-08-11 2000-08-11
US60224358 2000-08-11
PCT/IS2001/000015 WO2002013800A2 (fr) 2000-08-11 2001-08-10 Methode de prevention et de traitement des retinopathies

Publications (1)

Publication Number Publication Date
AU2001280093A1 true AU2001280093A1 (en) 2002-02-25

Family

ID=22840318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280093A Abandoned AU2001280093A1 (en) 2000-08-11 2001-08-10 Method for the prevention and treatment of retinopathy

Country Status (7)

Country Link
US (1) US20020055458A1 (fr)
EP (1) EP1307185B1 (fr)
AT (1) ATE292964T1 (fr)
AU (1) AU2001280093A1 (fr)
CA (1) CA2419158A1 (fr)
DE (1) DE60110087T2 (fr)
WO (1) WO2002013800A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
EP1633353A1 (fr) * 2003-05-30 2006-03-15 Merck & Co., Inc. Composition et procede de traitement de troubles maculaires
EP2500031A3 (fr) * 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions et procédés de traitement de la perméabilité vasculaire
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation
US7670794B2 (en) * 2005-11-04 2010-03-02 Washington University Managing glycemia status in diabetic patients
WO2008089521A1 (fr) 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Sensibilisateurs a l'iinsuline et procédés de traitement
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386098A (en) * 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4677115A (en) * 1984-12-12 1987-06-30 Merck & Co., Inc. Antiglaucoma thieno-thiopyran and thieno-thiepin sulfonamide derivatives, compositions, and method of use thereof
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
EP1058546A4 (fr) * 1998-03-06 2004-07-28 Univ Texas Traitement de troubles maculaires et composition appropriee
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
WO2004073708A1 (fr) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide et brimonidine pour le traitement d'etats oculaires

Also Published As

Publication number Publication date
EP1307185A2 (fr) 2003-05-07
WO2002013800A2 (fr) 2002-02-21
DE60110087T2 (de) 2005-09-29
EP1307185B1 (fr) 2005-04-13
CA2419158A1 (fr) 2002-02-21
DE60110087D1 (de) 2005-05-19
ATE292964T1 (de) 2005-04-15
WO2002013800A3 (fr) 2002-05-02
US20020055458A1 (en) 2002-05-09

Similar Documents

Publication Publication Date Title
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
WO2004089296A3 (fr) Inhibiteurs ameliores pour hydrolase epoxyde soluble
GEP20084317B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2002076499A3 (fr) Traitement combine du cancer du pancreas
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
AUPR839001A0 (en) Dosage form, device and methods of treatment
AU2002215261A1 (en) Method and arrangement for treatment of fluid
AU2002367979A1 (en) Devices, systems and methods for reducing levels of pro-inflammartory or anti-inflammatrory stimulators or mediators in blood products
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
WO2003059267A3 (fr) INHIBITEURS SELECTIFS DE 11β-HSD ET LEURS PROCEDES D'UTILISATION
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2002028434A3 (fr) Medicaments
AU2002231095A1 (en) Method and composition for the treatment of diabetic neuropathy
WO2002005848A3 (fr) Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
HK1044933A1 (en) Branched chain amino acid-dependent aminotranserase inhibitors and their use in the treatment of diabetic retinopathy.
PL312908A1 (en) Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
AU2003291368A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
WO2003059332A3 (fr) Traitement de l'uveite
WO2001044235A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
AU2811400A (en) Stable formulation containing fumagillin
WO2002024223A3 (fr) Prevention et traitement d'une infection streptococcique et staphylococcique